Skip to main content
Erschienen in: Wiener klinische Wochenschrift 19-20/2012

01.10.2012 | original article

Thyrotropin-secreting pituitary adenomas: diagnosis and management of patients from one Chinese center

verfasst von: Weiwei Zhao, MD, Hongying Ye, MD, Yiming Li, MD, Linuo Zhou, MD, Bin Lu, MD, Shuo Zhang, MD, Jie Wen, MD, Shiqi Li, MD, Yehong Yang, MD, Renming Hu, MD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 19-20/2012

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Thyrotropin-secreting pituitary adenoma (TSHoma) is rare and it is also a rare cause of thyrotoxicosis. Failure to detect the presence of TSHoma may result in dramatic consequences. This study is a review of our experience in the management of TSHoma at Huashan Hospital, China.

Methods

We followed up eight patients with TSHoma (five males and three females) between 2006 and 2011. The patients’ medical records were retrieved, and the demographic data, clinical presentation and management, final outcomes and follow-up were reviewed, and surgery performed.

Results

All the eight patients had unsuppressed TSH levels with elevated thyroid hormone levels; and neuroimaging revealed pituitary lesions. Five patients (62.5 %) were previously misdiagnosed as primary hyperthyroidism. They received pituitary adenomectomy, somatostatin analogs, and/or radiotherapy after definitive diagnosis. Serum TSH and thyroid hormone levels of all the patients restored to the normal levels during the follow-up.

Conclusions

Adenomectomy is not curative in many TSHoma patients, it should be adjuvantly treated by pharmacological and/or radiotherapy, frequently. A combination of adenomectomy, somatostatin analogs, and radiotherapy is often required for long-term management of the disease.
Literatur
1.
Zurück zum Zitat Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1996;81:3084–3090.PubMedCrossRef Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1996;81:3084–3090.PubMedCrossRef
2.
Zurück zum Zitat DeLellis RA, Lloyd RV, Heitz PU, et al. Tumours of the pituitary. In: DeLellis RA, Lloyd RV, Heitz PU, et al. editors. World Health Organization classification of tumours: pathology and genetics—tumours of endocrine organs. Lyon: IARC; 2004. pp. 9–39. DeLellis RA, Lloyd RV, Heitz PU, et al. Tumours of the pituitary. In: DeLellis RA, Lloyd RV, Heitz PU, et al. editors. World Health Organization classification of tumours: pathology and genetics—tumours of endocrine organs. Lyon: IARC; 2004. pp. 9–39.
3.
Zurück zum Zitat Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23:597–606.PubMedCrossRef Beck-Peccoz P, Persani L, Mannavola D, Campi I. Pituitary tumours: TSH-secreting adenomas. Best Pract Res Clin Endocrinol Metab. 2009;23:597–606.PubMedCrossRef
4.
Zurück zum Zitat Beck-Peccoz P, Persani L. TSH-producing adenomas. In: DeGroot LJ, Jameson JL editors. Endocrinology, 5th ed. Philadelphia: Elsevier Saundres; 2006. pp. 475–484. Beck-Peccoz P, Persani L. TSH-producing adenomas. In: DeGroot LJ, Jameson JL editors. Endocrinology, 5th ed. Philadelphia: Elsevier Saundres; 2006. pp. 475–484.
5.
Zurück zum Zitat Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 2002;5:83–88.PubMedCrossRef Beck-Peccoz P, Persani L. Medical management of thyrotropin-secreting pituitary adenomas. Pituitary 2002;5:83–88.PubMedCrossRef
7.
Zurück zum Zitat Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol. 2005;62:176–181.CrossRef Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U, et al. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol. 2005;62:176–181.CrossRef
8.
Zurück zum Zitat Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610–638.PubMed Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev. 1996;17:610–638.PubMed
9.
Zurück zum Zitat Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148:433–442.PubMedCrossRef Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J, et al. The changing spectrum of TSH-secreting pituitary adenomas: diagnosis and management in 43 patients. Eur J Endocrinol. 2003;148:433–442.PubMedCrossRef
10.
Zurück zum Zitat Sanno N, Teramoto A, Osamura RY. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg. 2000;93:194–200.PubMedCrossRef Sanno N, Teramoto A, Osamura RY. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg. 2000;93:194–200.PubMedCrossRef
11.
Zurück zum Zitat Wu YY, Chang HY, Lin JD, Chen KW, Huang YY, Jung SM. Clinical characteristics of patients with thyrotropin-secreting pituitary adenoma. J Formos Med Assoc. 2003;102:164–171.PubMed Wu YY, Chang HY, Lin JD, Chen KW, Huang YY, Jung SM. Clinical characteristics of patients with thyrotropin-secreting pituitary adenoma. J Formos Med Assoc. 2003;102:164–171.PubMed
12.
Zurück zum Zitat Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999;84:476–486.PubMedCrossRef Brucker-Davis F, Oldfield EH, Skarulis MC, Doppman JL, Weintraub BD. Thyrotropin-secreting pituitary tumors: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab. 1999;84:476–486.PubMedCrossRef
13.
Zurück zum Zitat Weiss RE, Refetoff S. Resistance to thyroid hormone: Rev Endocr Metab Disord. 2000;1:97–108. Weiss RE, Refetoff S. Resistance to thyroid hormone: Rev Endocr Metab Disord. 2000;1:97–108.
14.
Zurück zum Zitat Elston MS, Conaglen JV. Clinical and biochemical characteristics of patients with thyroid-stimulating hormone-secreting pituitary adenomas from one New Zealand centre. Intern Med J. 2010;40:214–219.PubMedCrossRef Elston MS, Conaglen JV. Clinical and biochemical characteristics of patients with thyroid-stimulating hormone-secreting pituitary adenomas from one New Zealand centre. Intern Med J. 2010;40:214–219.PubMedCrossRef
15.
Zurück zum Zitat Zielinski G, Podgorski JK, Warczynska A, Koziarski A, Zgliczynski W. Thyrotropin-TSH secreting pituitary tumor. Przegl Lek. 2002;59:1018–1023 (Abstract).PubMed Zielinski G, Podgorski JK, Warczynska A, Koziarski A, Zgliczynski W. Thyrotropin-TSH secreting pituitary tumor. Przegl Lek. 2002;59:1018–1023 (Abstract).PubMed
16.
Zurück zum Zitat Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, et al. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long term response to octreotide therapy. Endocr J. 2007;54:133–138.PubMedCrossRef Yoshihara A, Isozaki O, Hizuka N, Nozoe Y, Harada C, Ono M, et al. Expression of type 5 somatostatin receptor in TSH-secreting pituitary adenomas: a possible marker for predicting long term response to octreotide therapy. Endocr J. 2007;54:133–138.PubMedCrossRef
Metadaten
Titel
Thyrotropin-secreting pituitary adenomas: diagnosis and management of patients from one Chinese center
verfasst von
Weiwei Zhao, MD
Hongying Ye, MD
Yiming Li, MD
Linuo Zhou, MD
Bin Lu, MD
Shuo Zhang, MD
Jie Wen, MD
Shiqi Li, MD
Yehong Yang, MD
Renming Hu, MD
Publikationsdatum
01.10.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 19-20/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0216-z

Weitere Artikel der Ausgabe 19-20/2012

Wiener klinische Wochenschrift 19-20/2012 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Veranstaltungen